Brokerages Set Perspective Therapeutics, Inc. (NYSE:CATX) Price Target at $20.63

Perspective Therapeutics, Inc. (NYSE:CATX) has been assigned a consensus recommendation of “Buy” from the ten ratings firms that are presently covering the company, MarketBeat Ratings reports. Ten analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have covered the stock in the last year is $20.63.

Several research analysts have recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Perspective Therapeutics in a report on Monday, September 9th. UBS Group began coverage on Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 target price on the stock. Royal Bank of Canada cut their price target on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a report on Friday, August 16th. Truist Financial assumed coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They set a “buy” rating and a $21.00 price target on the stock. Finally, Oppenheimer restated an “outperform” rating and issued a $22.00 price objective on shares of Perspective Therapeutics in a research report on Friday, October 11th.

Perspective Therapeutics Stock Performance

Shares of CATX opened at $11.79 on Tuesday. The firm’s 50-day moving average price is $13.18. Perspective Therapeutics has a 12-month low of $2.20 and a 12-month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.04. The business had revenue of $0.53 million during the quarter. Analysts anticipate that Perspective Therapeutics will post -0.87 EPS for the current fiscal year.

Hedge Funds Weigh In On Perspective Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Bleakley Financial Group LLC acquired a new stake in shares of Perspective Therapeutics during the 1st quarter worth approximately $40,000. nVerses Capital LLC acquired a new stake in shares of Perspective Therapeutics in the 3rd quarter valued at $57,000. US Bancorp DE increased its stake in shares of Perspective Therapeutics by 142.7% in the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after purchasing an additional 3,866 shares during the last quarter. Victory Capital Management Inc. acquired a new position in shares of Perspective Therapeutics during the 2nd quarter worth $117,000. Finally, Point72 DIFC Ltd bought a new stake in shares of Perspective Therapeutics during the 2nd quarter worth $118,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.